SCL

Business Context and Reporting Period

Company: Stepan Company
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2005
Business Overview: Stepan Company manufactures and markets specialty chemicals, primarily surfactants, polymers, and specialty products. The company operates globally with significant exposure to raw material cost fluctuations and foreign currency exchange rates.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 19% ($42.9 million) year-over-year. This was driven primarily by higher selling prices ($31.4 million) to offset rising raw material costs, a 4% volume increase, and favorable foreign currency translation ($3.7 million).
• Profitability Decline: Net income decreased 20% to $3.2 million. Despite higher sales, gross profit remained flat due to raw material inflation. Operating income fell 14% due to a $1.3 million increase in operating expenses, largely driven by higher research and development costs.
• Segment Performance:
  • Surfactants: Sales up 14%, but operating income down 21% due to weak margins in the U.K. and higher expenses.
  • Polymers: Sales up 53% and operating income up 62%, driven by volume growth in polyurethane polyols and price increases.
  • Specialty Products: Sales down 27% and operating income down 76% due to a significant drop in pharmaceutical product volume.
• Cash Flow: Operating cash flow turned significantly negative ($25.3 million used) compared to the prior year ($6.0 million used), primarily due to a $38.1 million increase in working capital requirements (receivables and inventory buildup).
• Debt Levels: Total debt increased by $32.9 million to $144.9 million, funded largely by revolving credit facilities to support working capital needs.

Guidance, Outlook, and Risks

• Outlook: Management expects specialty products earnings to recover in the second quarter. Despite a slow start, management remains optimistic about full-year earnings growth. Raw material costs are expected to remain volatile with an overall upward trend for the remainder of 2005.
• Capital Expenditures: Expected to range between $40.0 million and $46.0 million for 2005, compared to $33.8 million in 2004.
• Environmental and Legal Contingencies: The company is a potentially responsible party at 21 waste disposal sites. The estimated range of possible losses is $8.4 million to $39.7 million, with an accrued liability of $18.5 million as of March 31, 2005. Specific sites include Maywood (NJ), Ewan and D'Imperio (NJ), and Wilmington (MA).
• Accounting Changes: Effective January 1, 2005, corporate manufacturing expenses are now charged to operating segments rather than unallocated corporate expense, impacting segment operating income comparability.
• Risks: Key risks include the ability to pass on raw material price increases, foreign currency fluctuations, and the outcome of environmental litigation.

Investor Verification Checklist

• Raw Material Pass-Through: Verify the company's ability to sustain price increases in the Surfactants segment, particularly in the U.K., where margins remain weak.
• Specialty Products Recovery: Monitor Q2 and Q3 results to confirm the anticipated recovery in pharmaceutical product volumes.
• Working Capital Management: Assess the sustainability of the $38.1 million working capital drawdown and its impact on future liquidity.
• Environmental Liabilities: Review updates on the Maywood and Ewan/D'Imperio site remediation costs to ensure the $18.5 million accrual remains adequate.
• Debt Covenants: Confirm continued compliance with loan agreements, specifically regarding financial ratios, given the increased debt load.